DLA-DQB1 alleles and bone marrow transplantation experiments in narcoleptic dogs

Tissue Antigens

Volumn 56, Issue 3, 2000, Pages 223-231

  Wagner, J L ^a,b,c   Storb, R ^a,b   Storer, B ^a,b   Mignot, E ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Animal model; Bone marrow transplantation; Canine narcolepsy; DLA DQB1

Indexed keywords

DOG LEUKOCYTE ANTIGEN DQB1; LEUKOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DOG; GENE DISRUPTION; GENETIC LINKAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; NARCOLEPSY; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BONE MARROW TRANSPLANTATION; DOG DISEASES; DOGS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HLA-DQ ANTIGENS; LINKAGE (GENETICS); MALE; MUTATION; NARCOLEPSY; PEDIGREE; POLYMORPHISM, GENETIC; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE;

EID: 0033822002     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2000.560304.x     Document Type: Article

References (51)

1. Narcolepsy
2. Genetic and familial aspects of narcolepsy
3. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive
4. Genetic markers in narcolepsy
5. Diagnostic criteria for narcolepsy and HLA-DR2 frequencies
6. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients
7. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and Black Americans
8. Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients
9. Mignot E. HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups
10. HLA class II haplotype and sequence analysis support a role for DQ in narcolepsy
11. Identification of a novel HLA narcolepsy susceptibility subtype, HLA- DQB1*0301
12. DQB1-0602 (DQw1) is not present in most non DR2 Caucasian narcoleptics
13. HLA class II and narcolepsy in thirty-three multiplex families
14. Canine model of narcolepsy: Genetic and developmental determinants
15. Narcolepsy in a dog and a cat
16. Narcolepsy-cataplexy in a female dog
17. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene
18. Hypocretin (orexin) deficiency in human narcolepsy
19. Organization of the canine major histocompatibility complex: Current perspectives
20. Molecular analysis and polymorphism of the DLA-DQB genes
21. Restriction fragment length polymorphism in canine narcolepsy
22. Narcolepsy without unique MHC class II antigen association: Studies in the canine model
23. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing
24. Nomenclature for factors of the dog major histocompatability system (DLA), 1998. First report of the ISAG DLA Nomenclature Committee
25. Genetic linkage of autosomal recessive canine narcolepsy with an immunoglobulin heavy-chain switch-like segment PNAS
26. DNA sequence and characterization of human major histocompatability complex beta chains from the DR1 haplotype PNAS
27. Sequential tests for the detection of genetic linkage
28. The likelihood method of linkage analysis
29. A simple restriction fragment-length polymorphism assay for MHC class II gene testing of dog families
30. Histocompatablility testing of dog families with highly polymorphic microsatellite markers
31. Experimental techniques used to study the immune system of dogs and other large animals
32. Syngerism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated grafts
33. Use of (CA)(n) polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting
34. Heterozygocity at the canarc-1 locus can confer susceptibility for narcolepsy: Induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoamninergic and cholinergic systems
35. Mutation screening of hypocretin system genes in human narcoleptics
36. Hypocretin levels in narcoleptic (hypocretin receptor-2 mutated) and control Dobermans
37. Interbreed variation of DLA-DRB1, DQA1 alleles and haplotypes in the dog
38. Monoclonal antibodies to HLA-DRw determinants
39. Pharmacological aspects of human and canine narcolepsy
40. Characterization of class II alpha genes and DLA-D region allelic associations in the dog
41. Restriction fragment length polymorphism of the major histocompatability complex of the dog
42. Nucleotide sequence and polymorphism analysis of canine DRA cDNA clones
43. Molecular analysis of the DLA-DR subregion Tissue Antigens
44. Molecular analysis and polymorphism of the DLA-DQA gene
45. An integrated linkage-radiation hybrid map of the canine genome
46. Class II antigens on canine lymphocytes
47. Phenotypic changes associated with activation of CD45 RA+ and CD45RO+ T cells
48. Genetic susceptibility to gluten sensitive enteropathy in Irish setter dogs is not linked to the major histocompatibility complex
49. The HLA class II genes and products: The HLA-D region
50. Major histocompatibility class II molecules in the CNS: Increased microglial expression at the onset of narcolepsy in a canine model
51. Neuronal degeneration in canine narcolepsy